Clinical Trial Update: A Study of the Safety and Efficacy of Subcutaneously Administered REGN475 in Patients With Osteoarthritis of the Knee [Phase 2]

View source ↗

Summary

A Phase 2 study of subcutaneously administered REGN475 for osteoarthritis of the knee was withdrawn. No results or further development details were provided in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoarthritis

Drugs mentioned

• REGN475 (REGN475)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Osteoarthritis | Phase 2 | Status: WITHDRAWN